BiotechTube

LY2157299 + Lomustine

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioma

Conditions

Glioma

Trial Timeline

Dec 15, 2005 → Sep 30, 2024

NCT ID
NCT01682187

About LY2157299 + Lomustine

LY2157299 + Lomustine is a phase 1 stage product being developed by Eli Lilly for Glioma. The current trial status is completed. This product is registered under clinical trial identifier NCT01682187. Target conditions include Glioma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01682187Phase 1Completed

Competing Products

20 competing products in Glioma

See all competitors
ProductCompanyStageHype Score
TemozolomideNovocurePhase 1
28
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
33
DS-1001bDaiichi SankyoPhase 2
52
DS-1001bDaiichi SankyoPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
41
Temozolomide and BevacizumabEisaiPhase 2
52
TemozolomideEisaiPhase 2
52
Gliadel Wafer + TemozolomideEisaiPhase 2
52
Palonosetron (PALO)EisaiPhase 2
52
Gliadel/Avastin/CPT-11EisaiPhase 2
52
Lenvatinib + BevacizumabEisaiPhase 2
52
Granisetron + OndansetronKyowa KirinPhase 2
52
Binimetinib 15 MGOno PharmaceuticalPhase 2
52
EnzastaurinEli LillyPhase 2
52
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
33
LY2157299 + Radiation + TemozolomideEli LillyPhase 1/2
41
Abemaciclib + TemozolomideEli LillyPhase 2
52
DSP-0390Sumitomo PharmaPhase 1
33
DSP-0390Sumitomo PharmaPhase 1
33
ApatinibJiangsu Hengrui MedicinePhase 2
52

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85